Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Purdue Pharma completes chapter 11 restructuring
We advised Purdue in connection with its nearly seven year-long chapter 11 restructuring
GH Research $200 million at-the-market offering
We advised GH Research on the establishment of the at-the-market program
METiS TechBio HK$2.43 billion IPO
We advised METiS TechBio on its IPO and HKEX listing
Tempus AI $460 million convertible senior notes offering
We advised the representatives of the several initial purchasers on the offering
Personalis $150 million at-the-market offering
We advised the sales agents on the offering
Viridian Therapeutics $250 million convertible senior notes offering
We acted as special product counsel to the representatives of the several underwriters on the offering
Alector $125 million at-the-market offering
We advised the sales agent on the offering
Roche acquisition of PathAI
We are advising Roche on the transaction
Cross Country Healthcare sale to Knox Lane
We are advising Cross Country Healthcare on the transaction
CellCentric $220 million Series D financing round
We advised Venrock Healthcare Capital Partners